AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04059354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech therapy addressing phonology and motor learning
Description: Determine the efficacy of a newly devised intensive speech treatment plan (DS-DxTx) focusing on vowels that combines efficacious treatment approaches to use with individuals with Down syndrome. The phonological speech intervention, Phonological Cycles approach, is designed for use with children with highly unintelligible speech and the speech motor learning intervention, Script training is a functional treatment to promote phrase level productions. Both approaches are documented to be efficacious with other speech disorders. The proposed approach takes into account the multiple deficits commonly present in individuals with DS, and based on the acoustic and perceptual finding on vowels from our VTLab. Acoustic and perceptual measures will be used to assess treatment efficacy.
Study NCT02381795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Carbon Dioxide
Study NCT00460499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A IV Insulin drip
Description: These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
Study NCT00460499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B Low Dose GIK
Description: These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
Study NCT00460499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C High Dose GIK
Description: This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
Study NCT01709240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioWeld1 System
Description: External skin layer closure of C-section incision by the BioWeld1 system. Removal of Chitoplast on day 4-7 post procedure.
Study NCT03797391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMB-01
Description: In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks).~Participants may continue to receive study drug until discontinuation criteria are met.
Study NCT01278316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
Study NCT01278316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
Study NCT01565395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incobotulinum Toxin A
Description: Xeomin 70-100 units injected in the parotid and submandibular glands of subjects
Study NCT01565395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sterile preservative free 0.9% saline
Study NCT04036994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation therapy
Description: All patients will undergo photobiomodulation therapy sessions three times a week for the total duration of 12 weeks starting at their last CT administration.
Study NCT00693472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: Preladenant, one 25 mg capsule, administered orally every 12 hours
Study NCT00693472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule administered orally every 12 hours
Study NCT00693472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anticholinergic agents or propanolol
Description: Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol.
Study NCT00693472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticholinergic agents or propanolol
Description: Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol.
Study NCT00693472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic agents or propanolol
Description: Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol.
Study NCT00693472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Haloperidol
Description: Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
Study NCT05087407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting seton
Description: Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
Study NCT04094207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day
Study NCT04094207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline tablet PLUS Risperidone 2 mg tablet up to 6 mg/day
Study NCT01244997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant
Description: This is designed to compare the response of the crestal bone after implants are placed whether delayed or immediately after tooth extraction in the maxilla.
Study NCT01244997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant
Description: This is designed to compare the response of the crestal bone after implants are placed whether delayed or immediately after tooth extraction in the maxilla.
Study NCT00693472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
Study NCT00693472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
Study NCT01743404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inflaminat
Study NCT01743404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Inflaminat 500 mg tablet
Study NCT04311827 — intervention group
Intervention type: OTHER
Intervention: Serratus Anterior Plane Block
Description: Injection of bupivacaine 75mg above the serratus anterior facial plane in the anterior axillary line
Study NCT04485572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Straight Leg Raise test (SLR) and Bragard test (B)
Description: The following neurodynamic and/or orthopedic tension tests were done: the Straight Leg Raise test (SLR), the Bragard test (B) and another test which was the combined test of both (SLR+B)
Study NCT04485572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fajersztajn test (F) and Sicard test (S)
Description: The following neurodynamic and/or orthopedic tension tests were done: the Fajersztajn test (F), the Sicard test (S) and another test which was the combination of both (F+S)
Study NCT04485572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Passive Neck Flexion test (PNF)and Kernig test (K)
Description: The following neurodynamic and/or orthopedic tension tests were done: the Passive Neck Flexion test (PNF), the Kernig test (K) and another test which was the combination of both (PNF+K)
Study NCT04485572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Slump test (ST) and Dejerine triad (DT)
Description: The following neurodynamic and/or orthopedic tension tests were done: the Slump test (ST), the Dejerine triad (DT) and another test which was the combination of both (ST+DT)
Study NCT04485572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard
Study NCT03568955 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: International Prolonged Grief Disorder Scale (IPGDS)
Description: Assessment measure for Prolonged Grief disorder based on the ICD-11 (International Classification of Disorders) criteria for PGD (Prolonged Grief Disorder). 15 items
Study NCT00677755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone combined misoprostol
Description: women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
Study NCT00677755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol alone protocol
Description: patients were only administered 0.8 mg of misoprostol orally on day 3.
Study NCT01883648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coconut Oil Beverage
Description: There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
Study NCT01883648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
Study NCT03283397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EK-12
Description: 10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.
Study NCT03283397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INF beta-1a
Description: Active substance is INF beta-1a, 44 mcg in 0.5 mL solution
Study NCT02964832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Grasp method
Study NCT02964832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Armband-in-hand method
Study NCT02964832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Armband-on-arm method
Study NCT01651390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.
Study NCT01651390 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
Study NCT02177019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized health plan
Study NCT03209427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 200 μg
Description: Intrathecal injection of morphine 200 μg
Study NCT04313322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WJ-MSCs
Description: WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.
Study NCT03386734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLN biopsy only
Description: In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
Study NCT03386734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SLN biopsy + PLN dissection
Description: In active comparator arm, SLN dissection + full lymphadenectomy will be performed.
Study NCT02595697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: J-EMT for Toddlers with Autism
Description: Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
Study NCT04366375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PTX-3
Description: Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.
Study NCT03561701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oteseconazole (VT-1161)
Description: Oteseconazole (VT-1161) 150mg capsule
Study NCT03561701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule
Study NCT01347255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO90100 cutaneous spray, ointment
Description: once daily application, 4 weeks
Study NCT01347255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate
Description: once daily application, 4 weeks
Study NCT01347255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 90100 cutaneous spray, ointment, vehicle
Description: once daily application, 4 weeks
Study NCT01347255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet® ointment
Description: once daily application, 4 weeks
Study NCT03654001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
Study NCT03654001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balanced
Description: Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).
Study NCT01765153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance
Description: Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
Study NCT02496169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eucaLimus
Description: Percutaneous Coronary Intervention (PCI)
Study NCT00391001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurine
Description: double-blind, placebo-controlled, adjunctive medication
Study NCT00391001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Taurine
Description: double-blind, placebo-controlled, adjunctive medication
Study NCT01904656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Behind your health
Description: Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4.
Study NCT01765153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precision
Description: Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
Study NCT03032627 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of discarded heart tissue
Description: Discarded heart tissue will be collected from patients undergoing the aforementioned cardiac surgeries.
Study NCT03340662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122
Study NCT04320043 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior cervical decompression
Description: Any of the following anterior surgical techniques used to decompress the cervical nerve roots or spinal cord; corpectomy, Anterior Cervical Discectomy (ACD), Anterior Cervical Decompression and Fusion (ACDF) or ACDF with Plating
Study NCT01904656 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peaches
Description: Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4.
Study NCT04425785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise Program
Description: A structured exercise program
Study NCT04425785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: A structured cognitive behavioural therapy program
Study NCT01511809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir monotherapy
Description: Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
Study NCT00889200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 6 weeks standard oral therapy
Study NCT00275756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol (drug)
Description: Timolol (0.5%, non-selective beta-blocker, Timoptic®, Merck Sharp \& Dohme, Haarlem, Netherlands), dose 1 drop in one eye twice daily for two weeks
Study NCT00275756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dorzolamide (drug)
Description: Dorzolamide (2%, carbonic anhydrase inhibitor, Trusopt®, Laboratoires Merck Sharp \& Dohme - Chibret, France), dose: 1 drop in one eye twice daily for two weeks
Study NCT00275756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine (drug)
Description: Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®, Allergan Pharmaceuticals, Westport, Ireland), dose: 1 drop in one eye twice daily for two weeks
Study NCT00275756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry
Description: blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days
Study NCT00275756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements, in total 2x 5 measurements on two study days
Study NCT00275756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction cup method
Description: The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days
Study NCT01747252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RGC
Study NCT01747252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: The equivalent of 150 mg resveratrol
Study NCT00130923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Long Acting
Description: Dose 25.00, 37.50 or 50.00 mg q two weeks
Study NCT00130923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral risperidone
Description: 0.50-6.00 mg oral risperidone daily
Study NCT00360828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride (HCI) Treatment
Description: Irinotecan injections. Irinotecan hydrochloride \[CPT-11; CAMPTOSAR\] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.